Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades8
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Pharmaceuticals upbeat on new data from 'MATINS' study
11 Dec 2019 - Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
11 Dec 2019 - Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
29 Nov 2019 - Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
28 Nov 2019 - Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing
21 Nov 2019 - UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
8 Nov 2019 - Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
7 Nov 2019 - LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
1 Nov 2019
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Pharmaceuticals upbeat on new data from 'MATINS' study
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be ...
Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance
Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital
Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status
Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing
Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing
UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250
Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress
LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week
Follow the stocks
